Citadel Advisors’s Genprex GNPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Hold
0
-$736 14890
2023
Q4
Hold
0
13949
2023
Q3
Hold
0
13687
2023
Q2
Sell
-1
Closed -$37.2K 13185
2023
Q1
$36.3K Hold
1
﹤0.01% 12545
2022
Q4
$42.5K Hold
1
﹤0.01% 12333
2022
Q3
$48K Hold
1
﹤0.01% 11663
2022
Q2
$73K Hold
1
﹤0.01% 11672
2022
Q1
$130K Hold
1
﹤0.01% 12009
2021
Q4
$73K Hold
1
﹤0.01% 13005
2021
Q3
$75K Hold
1
﹤0.01% 13110
2021
Q2
$145K Sell
1
-1
-50% -$164K ﹤0.01% 12535
2021
Q1
$294K Hold
2
﹤0.01% 10906
2020
Q4
$277K Buy
2
+1
+100% +$155K ﹤0.01% 9210
2020
Q3
$81K Buy
+1
New +$158K ﹤0.01% 9383
2020
Q2
Hold
0
9363

Other funds holding GNPX

Citadel Advisors's GNPX Position: Q1 2024 in Review

Citadel Advisors sold out of Genprex (GNPX) in Q1 2024, closing a stake of 4 shares — an estimated $44K sold.

Citadel Advisors first reported a position in GNPX in Q2 2019 and held it in 8 quarters. The position peaked at $81K in Q1 2022. 8 funds tracked by Wall St. Rank hold GNPX as of Q1 2024.

  • Citadel Advisors reported no remaining Genprex position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 4 Genprex shares in Q1 2024, an estimated $44K.
  • Citadel Advisors first reported a position in Genprex in Q2 2019 and held it in 8 quarters.
  • Citadel Advisors's Genprex position peaked at $81K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Genprex as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.